Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic
  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Tonix Pharmaceuticals TNX-1500 monoclonal antibody published in American Journal of Transplantation

Tonix Pharmaceuticals CEO Seth Lederman joins Proactive's Natalie Stoberman to share the findings of two publications in the American Journal of Transplantation that demonstrate how the company's TNX-1500 monoclonal antibody product candidate aided in the prevention of organ rejection for kidney and heart transplants.

Lederman says these animal studies found that TNX-1500 retains activity to prevent rejection and preserve graft function. He adds that Tonix expects to start a first-in-human Phase 1 study in the second quarter of 2023 of TNX-1500 for prophylaxis of organ rejection in adult patients receiving a kidney transplant.

Contact Details

Proactive Studio

+1 347-449-0879

na-editorial@proactiveinvestors.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.